News | December 14, 2024
Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio
The trademark rights for these brands will be transferred to Lupin by March next year.
The trademark rights for these brands will be transferred to Lupin by March next year.
Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus
The company had earlier announced about the approval received from the MHRA for Liraglutide
Subscribe To Our Newsletter & Stay Updated
